Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety

Peter Weeke; Charlotte Andersson; Bente Brendorp; Christian Torp-Pedersen

doi:http://dx.doi.org/10.2217/14796678.4.6.559

Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety

Peter Weeke, Charlotte Andersson, Bente Brendorp, Christian Torp-Pedersen

Abstract

Vernakalant (RSD1235) is a novel antiarrhythmic agent for conversion of rapid onset atrial fibrillation (AF). It is an atria-selective multichannel ion blocker (blocks I(Kur), I(Na), I(Ca, L), I(to) and I(Kr)), with a small effect on ventricular repolarization. In clinical Phase II and III studies, vernakalant was moderately (approximately 50%) effective in converting AF of short duration (<7 days), and effective (approximately 70-80%) in converting AF of less than 72 h, but was not effective in converting long duration AF (>7 days) or atrial flutter. Vernakalant seems to have only a small proarrhythmic effect, with no reported cases of torsades de pointes in direct relation to vernakalant administration in Phase II and III studies. Overall, there are few reported serious adverse events.

Originalsprog	Engelsk
Tidsskrift	Future Cardiology
Vol/bind	4
Udgave nummer	6
Sider (fra-til)	559-67
Antal sider	9
ISSN	1479-6678
DOI	https://doi.org/10.2217/14796678.4.6.559
Status	Udgivet - 1 nov. 2008

Adgang til dokumentet

http://dx.doi.org/10.2217/14796678.4.6.559

Citationsformater

@article{166ddddef7b749bdaf305a122bd008f3,

title = "Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety",

abstract = "Vernakalant (RSD1235) is a novel antiarrhythmic agent for conversion of rapid onset atrial fibrillation (AF). It is an atria-selective multichannel ion blocker (blocks I(Kur), I(Na), I(Ca, L), I(to) and I(Kr)), with a small effect on ventricular repolarization. In clinical Phase II and III studies, vernakalant was moderately (approximately 50%) effective in converting AF of short duration (<7 days), and effective (approximately 70-80%) in converting AF of less than 72 h, but was not effective in converting long duration AF (>7 days) or atrial flutter. Vernakalant seems to have only a small proarrhythmic effect, with no reported cases of torsades de pointes in direct relation to vernakalant administration in Phase II and III studies. Overall, there are few reported serious adverse events.",

author = "Peter Weeke and Charlotte Andersson and Bente Brendorp and Christian Torp-Pedersen",

year = "2008",

month = nov,

day = "1",

doi = "http://dx.doi.org/10.2217/14796678.4.6.559",

language = "English",

volume = "4",

pages = "559--67",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Future Medicine Ltd.",

number = "6",

}

TY - JOUR

T1 - Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety

AU - Weeke, Peter

AU - Andersson, Charlotte

AU - Brendorp, Bente

AU - Torp-Pedersen, Christian

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Vernakalant (RSD1235) is a novel antiarrhythmic agent for conversion of rapid onset atrial fibrillation (AF). It is an atria-selective multichannel ion blocker (blocks I(Kur), I(Na), I(Ca, L), I(to) and I(Kr)), with a small effect on ventricular repolarization. In clinical Phase II and III studies, vernakalant was moderately (approximately 50%) effective in converting AF of short duration (<7 days), and effective (approximately 70-80%) in converting AF of less than 72 h, but was not effective in converting long duration AF (>7 days) or atrial flutter. Vernakalant seems to have only a small proarrhythmic effect, with no reported cases of torsades de pointes in direct relation to vernakalant administration in Phase II and III studies. Overall, there are few reported serious adverse events.

AB - Vernakalant (RSD1235) is a novel antiarrhythmic agent for conversion of rapid onset atrial fibrillation (AF). It is an atria-selective multichannel ion blocker (blocks I(Kur), I(Na), I(Ca, L), I(to) and I(Kr)), with a small effect on ventricular repolarization. In clinical Phase II and III studies, vernakalant was moderately (approximately 50%) effective in converting AF of short duration (<7 days), and effective (approximately 70-80%) in converting AF of less than 72 h, but was not effective in converting long duration AF (>7 days) or atrial flutter. Vernakalant seems to have only a small proarrhythmic effect, with no reported cases of torsades de pointes in direct relation to vernakalant administration in Phase II and III studies. Overall, there are few reported serious adverse events.

U2 - http://dx.doi.org/10.2217/14796678.4.6.559

DO - http://dx.doi.org/10.2217/14796678.4.6.559

M3 - Journal article

SN - 1479-6678

VL - 4

SP - 559

EP - 567

JO - Future Cardiology

JF - Future Cardiology

IS - 6

ER -

Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater